"Purdue Pharma already sells a tamper-resistant, long-acting form of oxycodone, so Remoxy's setback is a win for the privately held drug maker."
Anyone in the know who can tell me the advantages of 181 over purdue's "tamper-resistant, long-acting form of oxy?" Is 181 going to be a me-too drug or does its formulation which does not allow addicts to separate opioid, better than purdue's "tamper-resistant?
NKTR-181 is not a reformulation, it's not a prodrug, it's a NCE. The in tact PEG conjugated opiod is the active drug. PEG attenuates BBB penetration longer PEG = less penetration. In the case of NKTR-118 they put a PEG on an opiod antagonist of sufficient lenght to essentially prevent BBB penetration. For 181 the experiment is, how does the drug behave if you go half way? They use a shorter PEG to attenuate/slow BBB penetration, but not eliminate it. The in vivo behavior of NKTR-181 is a function of both the plasma half life and BBB drug transit.
Any reformulation can be circumvented by those inclined to do so. This is not the case with NKTR-181. Tamper resistant is effectively could become tamper proof this is a big difference. What this means in the clinic is yet to be determined, but if the hypothesis is correct, and the data to date is encouraging (very preliminary). The drug could be a hands down winner the goal is safer pain relief with less propensity for addiction and misdirection.
glad, i think the street.com article may have been sloppy. i don't know of a long acting purdue oxycodone other than oxycontin which when crushed or chewed gave a high and had high addiction and abuse potential. they stopped making that in 2010. if you or anyone knows of another prep made by purdue i would be interested in hearing about it.